Is Faster Better? Senators Question Surrogate Endpoints, Fast Track Status
Executive Summary
Several U.S. senators are using congressional inquiry mechanisms to challenge the fundamental underpinnings of rapid FDA drug review
You may also be interested in...
Hypertensives May Get Class Outcome Labels; Industry Wary Of Broad Efficacy
Two major drug companies with significant hypertension profiles are welcoming the proposed inclusion of class-wide cardiovascular outcomes data in antihypertensive drug labeling - in contrast to other firms that commented on the FDA draft guidance
Hypertensives May Get Class Outcome Labels; Industry Wary Of Broad Efficacy
Two major drug companies with significant hypertension profiles are welcoming the proposed inclusion of class-wide cardiovascular outcomes data in antihypertensive drug labeling - in contrast to other firms that commented on the FDA draft guidance
FDA Chief Scientist Torti’s Plan For First 100 Days Centers On Excellence
FDA's newly appointed Chief Scientific Officer Frank Torti will focus on collaborations with industry and academia in order to boost the agency's scientific expertise and augment scarce resources, he said at a May 30 Science Board Meeting